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Background: Bilastine, a novel non-sedating second-generation H1 antihistamine, has been approved in
most European countries since 2010. This study aimed to evaluate the superiority of bilastine over
placebo in Japanese patients with perennial allergic rhinitis (PAR).
Methods: This randomized, double-blind, placebo-controlled, parallel-group, phase III study (trial
registration number JapicCTI-142600) evaluated the effect of a 2-week treatment period with bilastine
(20 mg once daily), fexofenadine (60 mg twice daily), or a matched placebo (double dummy) in patients
with PAR. All patients were instructed to record individual nasal and ocular symptoms in diaries daily.
The primary endpoint was the mean change in total nasal symptom scores (TNSS) from baseline to Week
2 (Days 10e13).
Results: A total of 765 patients were randomly allocated to receive bilastine, fexofenadine, or placebo
(256, 254, and 255 patients, respectively). The mean change in TNSS from baseline at Week 2 was
signiﬁcantly decreased by bilastine (0.98) compared to placebo (0.63, P ¼ 0.023). Bilastine and fex-
ofenadine showed no signiﬁcant difference in the primary endpoint. However, the mean change in TNSS
from baseline on Day 1 was more signiﬁcantly decreased by bilastine (0.99) than by placebo (0.28,
P < 0.001) or fexofenadine (0.62, P ¼ 0.032). The active drugs also improved instantaneous TNSS 1 h
after the ﬁrst and before the second drug administration on Day 1 (P < 0.05). The study drugs were well
tolerated.
Conclusions: After 2-week treatment period, bilastine 20 mg once daily was effective and tolerable in
Japanese patients with PAR, and exhibited a rapid onset of action.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).logy-Head and Neck Surgery,
kyo 113-8602, Japan.
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Allergic rhinitis (AR) is one of the most common diseases in
worldwide. In the Practical Guideline for the Management of
Allergic Rhinitis in Japan,1,2 AR has been classiﬁed as seasonal orvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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pattern of exposure to a triggering aeroallergens and duration of
symptoms. SAR is associated with a wide variety of pollen allergens
including Japanese cedar pollen and, thus, depends on the
geographic location and climatic conditions, whereas PAR is most
frequently caused by Dermatophagoides allergens (a major antigen
in house dust or mites) in Japan.2,3 AR is a global health problem
that affects 10%e30% of the population.4,5 In 2008, the prevalence
rates of PAR, SAR, and AR were 23.4%, 29.8%, and 39.4%, respectively
in the Japanese population.1 The pathological characteristics of
both PAR and SAR are a type I allergic disease of the nasal mucosa
with associated nasal symptoms such as sneezing and rhinorrhea,
as well as nasal congestion or itching. AR symptoms are induced by
several chemical mediators released from the mast or inﬂamma-
tory cells and histamine is a particularly important mediator of AR
symptoms, especially sneezing, rhinorrhea, and nasal itching. Oral
H1-antihistamines are symptomatic treatment used to alleviate the
symptoms and associated discomfort of AR in everyday life. Newer
second-generation H1-antihistamines are highly selective for the
H1 receptor, and their penetration of the central nervous system is
limited. Therefore non-sedating, second-generation H1-antihista-
mines are the recommended drug therapy for AR in the present
guidelines.1,5,6 The advantages of oral H1-antihistamines include
rapid onset of action, once-daily dosing, and maintenance of efﬁ-
cacy with regular use.5
Bilastine is a novel non-sedating second-generation H1-anti-
histamine, which has been approved for the symptomatic treat-
ment of AR and urticaria in numerous countries (Europe, Central/
South America, and Africa).7 It is a potent and highly selective H1-
antihistamine8 with a good safety proﬁle.9 Studies in healthy vol-
unteers and patients have shown that bilastine does not affect
cardiac conduction10 or driving ability,11 satisﬁed positron emission
tomography (PET) criteria to be deﬁned as a non-sedating anti-
histamine,12 is not substantially metabolized in humans,13 and can
be safely administered to patients with different degrees of renal
insufﬁciency without the need for dose adjustments.14 In clinical
studies, bilastine 20 mg administered once daily exerted efﬁcacy in
AR was comparable to that of cetirizine15 and desloratadine,16
while its efﬁcacy in chronic idiopathic urticaria was comparable
to that of levocetirizine.17
This is the ﬁrst study to assess the efﬁcacy and safety of once
daily bilastine 20 mg versus (vs.) a placebo in Japanese patientsFig. 1. Studywith PAR. In addition, the efﬁcacy of bilastine was subsequently
compared to that of fexofenadine in a reference group of patients.
Methods
Study design
We conducted amulticenter, randomized, double-blind, placebo
controlled, parallel-group, pivotal Phase III study at four centers in
Japan between September 2014 and January 2015. The study
design, which is shown in Figure 1 consisted of observation and
treatment periods. The eligible patients commenced a 2-week
observational period and received placebo twice a day for at least
7 days to assess their baseline symptoms under single-blind con-
ditions before their registration. A total of 750 patients were
eventually randomly allocated (1:1:1) to one of three treatment
groups, bilastine 20 mg, fexofenadine 60 mg, or placebo (double
dummy). A non-deterministic minimization method with a
stochastic-biased coin was used in the randomization of patients.
The sum of the total nasal symptom scores (TNSS) over the 3 days
before the randomization (16, 23, and 24 points) were used as
stratiﬁcation factors of minimization to ensure a balance existed
between the treatment groups. Furthermore, the randomization
was performed centrally using a computer (ADJUST Co., Ltd., Sap-
poro, Japan).
The study drugs were supplied by Taiho Pharmaceutical and
were administered twice a day, in the morning 1 h before or 2 h
after breakfast and in the evening before or after dinner during the
observation and treatment periods (Supplementary Table 1). A
follow-up visit was scheduled 4e7 days after the end of the treat-
ment. The patients who completed all of their visits were consid-
ered to have completed the studywhile thosewhowere assigned to
a treatment and discontinued the study before the completion had
an early withdrawal visit to assess the safety and efﬁcacy at the end
of the treatment.
Patients
Patients were considered eligible for inclusion in the study if
they met the following eligibility criteria: aged 18e74 years, diag-
nosed with a 2-year or longer history of PAR, and had a positive
nasal provocation test with house dust disc and speciﬁcdesign.
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tive to at least one house dust mite, Dermatophagoides pter-
onyssinus or Dermatophagoides farinae) and were subsequently pre-
registered. The inclusion criteria for patient registration were: a
TNSS sum of 16 (up to 45 points) and a sum of rhinorrhea or
sneezing scores of 5 (up to 12 points) for 3 days before random-
ization, appropriately recorded symptom scores in the patient diary
during the last 3 days before both the preliminary registration and
registration, and an 80% or higher rate of both symptom score entry
in the patient diary and compliance during the observation period
of the registration.
Patients were excluded from the study if they had active in-
fections; nasal septal ulcers or polyps, and asthma, as well as any
other nasal, ocular, or ear disorders that could interfere with the
efﬁcacy evaluation (vasomotor, eosinophilic, acute/chronic, hyper-
trophic, and drug-induced rhinitis, as well as viral conjunctivitis,
otitis media, sinusitis, nasal polyps, repetitive nasal hemorrhage,
and treatment-requiring nasal septal deviation); a previous history
of intranasal surgery (such as laser therapy, coagulative necrosis,
and resection); speciﬁc immunotherapy (such as cedar pollen
sublingual immunotherapy for cedar pollinosis); or non-speciﬁc
modulation therapy in the previous 3 years; underwent immuno-
therapy or received corticosteroid injections or treatment with
humanized anti-IgE antibody (omalizumab) in the previous 180
days; taken other investigational drugs in the previous 90 days;
received corticosteroids or P-glycoprotein inhibitors in the previous
30 days; taken anti-allergic, antihistamine, anticholinergic, nasal/
ocular vasoconstrictor, non-prescription, or aluminum hydroxide/
magnesium hydroxide drugs in the previous 7 days before study
commencement. Furthermore, patients with a nasal congestion
score of 4 on at least 1 of the 3 days prior to registration; a daily
TNSS variation above 3 during the 3 days prior to registration; and a
3-day total TNSS before the randomization that had reduced by 40%
or more from total obtained 3 days before pre-registration were
also excluded. Similarly, patients who did not respond to treatment
with the usual antihistamine dose for PAR were excluded.
Efﬁcacy assessments
The primary efﬁcacy endpoint was the mean change in TNSS
from baseline at Week 2 (4 days: Days 10e13). The TNSS is the sum
of the individual scores for rhinorrhea, sneezing, and nasal
congestion and itching. The patients were instructed to record their
symptom scores (individual nasal and ocular symptoms) in the
patient diary daily during the observation and treatment periods.
The baseline values were the average scores during the 4 consec-
utive days prior to the day of drug administration (Day3 to 0). The
secondary efﬁcacy variables were the total ocular symptom score
(TOSS), total symptom score (TSS), individual nasal and ocular
symptom scores, instantaneous TNSS on Day 1, quality of life (QOL)
score using the Japanese Allergic Rhinitis QOL Standard Question-
naire No. 11, rhinoscopic ﬁndings, and degree of patient satisfaction
with treatment.
The sneezing, rhinorrhea or nasal congestion was evaluated
using ﬁve-point scale according to the Japanese Guideline.1 The
nasal itching score was based on a four-point scale: nasal itching
with frequent nose rubbing and blowing, 3; a nasal itch with oc-
casional nose rubbing and blowing, 2; a nasal itch that was not
persistent, 1; and no symptoms, 0. The severity of ocular symptoms
were scored using an individual ﬁve-point scale based on eye
itching (more severe symptoms than 3, 4; frequent eye rubbing, 3;
occasional eye rubbing, 2; no eye rubbing, 1; and no symptoms, 0)
and lacrimation (more severe symptoms than 3, 4; frequent tear
wiping, 3; occasional tear wiping, 2, no tear wiping from eyes, 1;
and no symptoms, 0).For the exploratory evaluation of the onset of action, patients
monitored and scored their instantaneous nasal symptoms (rhi-
norrhea, sneezing, and nasal congestion and itching) using a ﬁve-
point scale (no symptoms, 0; mild, 1; moderate, 2; severe, 3; and
extremely severe, 4) before (baseline) and 1 h after the ﬁrst drug
administration and before the second drug administration on Day
1. The rhinoscopic ﬁndings included swelling or discoloration of the
inferior turbinate mucosa and the quantity or properties of the
nasal discharge, which were scored using a four-point scale. The
degrees of satisfaction was scored on a ﬁve-point scale, which the
patients used to assess their level of satisfactionwith the treatment
efﬁcacy and safety (very satisﬁed, 5; satisﬁed, 4; acceptable, 3;
dissatisﬁed, 2; and very dissatisﬁed, 1). The degree of satisfaction
with the treatment was assessed during the last visit of the treat-
ment period.
Safety assessments
The safety was assessed based on the incidence and severity of
the adverse events (AEs), vital signs (axillary body temperature and
supine blood pressure and pulse rate), laboratory tests (clinical
chemistry, hematology, and urinalysis), and a 12-lead electrocar-
diogram (ECG). The AEs were monitored during the treatment and
follow-up period. Treatment compliance was assessed through the
patient diary card recording. The causal relationships between all
the AEs and the drug were categorized by the investigator as
probable, possible, unlikely, or unrelated.
Statistical analyses
The objective of this study was to verify the superiority of
bilastine 20 mg over placebo, which was the primary efﬁcacy
endpoint for the full analysis set (FAS) population. A sample size of
678 patients (226 per group) was required to provide a statistical
power of 90% at a two-sided level of signiﬁcance of 5%, assuming a
treatment difference of 0.75 and a standard deviation (SD) of 2.45,
based on a previous study.18 Assuming that approximately 10% of
the patients might withdraw from the study, the ﬁnal sample size
required was calculated to be 750 patients (250 per group).
The efﬁcacy analyses were performed for the full analysis set
(FAS) of patients who were randomized to a treatment, received at
least one dose of the study drug, completed the study without
violating the patient inclusion and exclusion criteria protocol, and
completed the diary assessment of the TNSS for at least 2 days in
the study from Day 10e13.
For the primary efﬁcacy endpoint, the superiority of bilastine
20 mg to placebo was analyzed using an analysis of covariance
(ANCOVA) model including treatment as a factor with baseline and
institution as a covariate. There were four participating institutions.
For the secondary efﬁcacy endpoints, the mean change from
baseline in TNSS, TOSS, TSS, each symptom score, and the instan-
taneous TNSS on Day 1 were analyzed using the same ANCOVA
model. The mean change from baseline in the daily TNSS and the
QOL scores were analyzed using the Student's t-test. For the degree
of satisfaction and rhinoscopic ﬁndings, the differences between
the two treatment groups were assessed using a pairwise com-
parison, using the Fisher's exact or Wilcoxon two-sample tests.
The safety analyses were performed on the safety population
(SP) of patients who received at least, one dose of the study drug.
The incidences of AEs and adverse drug reactions (ADRs) were
analyzed using the Fisher's exact tests. The AEs were coded using
the Medical Dictionary for Regulatory Activities (MedDRA) version
17.1.
All the statistical analyses were performed using the statistical
analysis software (SAS) version 9.2 (SAS Institute, Cary, NC, USA). All
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ered statistically signiﬁcant.Ethical approval and clinical trial registration
This trial was conducted in accordance with the World Medical
Association Declaration of Helsinki and the Japanese Good Clinical
Practice Guidelines. The study protocol was approved by the
Institutional Review Boards of all participating institutions.
Informed consent was obtained from all the participants included
in the study, which was registered with the Japan Pharmaceutical
Information Center (number JapicCTI-142600).Results
Study population
A total of 1001 patients were initially screened for the study out
of which 236 (23.6%) were excluded, and the remaining 765 pa-
tients were randomly allocated to three treatment groups. The
groups were bilastine, fexofenadine, and placebo with 256, 254,
and 255 patients, respectively (Fig. 2). Themost common reason for
patient exclusionwas the failure to meet the eligibility criteria (222
patients, 94.1%). One patient assigned to bilastine was excluded
from the safety analysis because the patient did not take a study
drug. Twenty-one patients were withdrawn from the study
(bilastine, ﬁve [2.0%]; placebo, seven, [2.7%], and fexofenadine, nine
[3.5%]). Of the 765 randomized patients, 744 (>97%) completed the
study, 747 were included in the efﬁcacy analysis (FAS), and 764
were included in the safety analysis (SP).Fig. 2. Flow chart of patient enrollment and disposition. #PaThe demographic and baseline characteristics of the FAS popu-
lation were similar for the three groups and are summarized in
Supplementary Table 2. The mean rate of treatment compliance
was also similar for the three study groups (placebo, 98.95%;
bilastine, 99.26%; and fexofenadine, 99.05%).Efﬁcacy
The result of the primary endpoint analysis revealed a mean
change in the TNSS from baseline at Week 2 (Table 1) of0.98 (95%
conﬁdence interval [CI], 1.19 to 0.77) in bilastine and 0.63
(0.84 to 0.42) in placebo. The estimated difference in the
adjusted mean between bilastine and placebo was 0.35 (0.65
to 0.05). Because the p-value (P ¼ 0.023) of the between-group
statistical test was lower than the prespeciﬁed signiﬁcance level
of two-sided 5%, the superiority of bilastine 20 mg to placebo was
conﬁrmed. Furthermore, the secondary analysis of the primary
endpoint was performed to compare the efﬁcacy of bilastine and
fexofenadine. The estimated mean change in the TNSS was 0.96
(1.17 to 0.75) in fexofenadine, and the estimated difference in
the adjusted mean between bilastine and fexofenadine was 0.00
(0.31 to 0.31). The difference between bilastine and fexofenadine
was not statistically signiﬁcant in the primary endpoint (P ¼ 0.999,
Table 1).
The mean change in the daily TNSS from baseline during the
treatment period is presented in Figure 3. The TNSS of placebo
decreased gradually from baseline in a treatment day-dependent
manner. The mean ± SD change in the TNSS of placebo, bilastine,
and fexofenadine from baseline on Day 1
was 0.28 ± 1.67, 0.99 ± 1.87, and 0.62 ± 1.90, respectively.
There were statistically signiﬁcant differences between active drugtient included due to discontinued intervention (n ¼ 5).
Table 1
Primary endpoint: mean change in total nasal symptom score (TNSS) from baseline at Week 2 in full analysis set (FAS).
Placebo (n ¼ 251) Bilastine (n ¼ 249) Fexofenadine (n ¼ 247)
Baseline Mean ± SD 7.33 ± 1.49 7.48 ± 1.54 7.38 ± 1.43
Week 2 Mean ± SD 6.73 ± 1.87 6.48 ± 2.12 6.42 ± 1.97
Estimated mean change (95% CI) 0.63 (0.84 to 0.42) 0.98 (1.19 to 0.77) 0.96 (1.17 to 0.75)
Estimated mean differencey(95% CI) e 0.35 (0.65 to 0.05) 0.34 (0.64 to 0.04)
P-value vs. placebo e 0.023 0.027
Estimated mean differenceyy(95% CI) e 0.00 (0.31 to 0.31) e
P-value vs. fexofenadine e 0.999 e
Analysis of covariance (ANCOVA) model including treatment as factor with baseline and institution as covariates. CI, conﬁdence interval; estimated mean difference
y ¼ estimated mean change in bilastine or fexofenadine minus estimated mean change in placebo. Estimated mean differenceyy ¼ estimated mean change in fexofenadine
minus estimated mean change in bilastine. Week 2, change in mean score for treatment period Day 10e13 (4 days) compared with baseline (for total 4 days: Day 3 to 0).
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signiﬁcantly greater than that of fexofenadine on Day 1 (P ¼ 0.032).
The mean change in the daily TNSS from baseline for bilastine
showed a constant decrease from Day 1e13 (approximately 1.0).
On the other hand, the mean change in the daily TNSS of the fex-
ofenadine showed a gradual decrease until Day 3 andwas similar to
that of bilastine on Day 3 and after that.
Table 2 shows the estimated mean change from baseline in the
TNSS and four individual nasal symptoms over the 2-week treat-
ment period. Both bilastine and fexofenadine showed a signiﬁ-
cantly improved TNSS on Day 1e3, Week 1 (Day 4e7), compared to
placebo, and there were no signiﬁcant differences between bilas-
tine and fexofenadine at any period. The results of each nasal
symptom analyzed in the TNSS revealed that the mean change in
rhinorrhea and nasal itching from baseline for bilastine was more
signiﬁcantly decreased by Day 1e3 and Week 1, compared with
placebo. Bilastine also signiﬁcantly improved the sneezing but not
the nasal congestion at all examination periods (Day 1e3, Week 1
and 2). In the fexofenadine treatment, similar results were obtained
despite the lack of improvement in the rhinorrhea at any period.
The mean change from baseline in the TOSS at Day 1e3 and
Week 1 were signiﬁcantly greater for bilastine than for placebo (the
estimated difference [95% CI], P-value: 0.21 [0.35 to 0.07]
P¼ 0.004 by Day 1e3;0.15 [0.30 to0.01], P¼ 0.038 byWeek 1;
and 0.12 [0.27 to 0.03], P ¼ 0.133 by Week 2). The mean change
from baseline in TOSS by Day 1e3 and Week 1 and 2 were also
signiﬁcantly greater for fexofenadine than for placebo (0.27
[0.42 to 0.13], P < 0.001 by Day 1e3; 0.33 [0.47 to 0.18],Fig. 3. Change in daily total nasal symptom score (TNSS) from baseline over treatment p
fexofenadine vs. placebo (Student's t-test). yP < 0.05 for bilastine vs. fexofenadine (StudentP < 0.001 by Week 1; and 0.30 [0.45 to 0.15], P < 0.001 by
Week 2). There were statistically signiﬁcant differences in the TOSS
between bilastine and fexofenadine byWeek 1 and 2 (0.17 [0.32
to 0.03], P ¼ 0.022 by Week 1; and 0.18 [0.33 to 0.03],
P ¼ 0.020 by Week 2). The results of each ocular symptom evalu-
ation performed for the TOSS, revealed that the mean change in eye
itching from baseline was more signiﬁcantly decreased by Day 1e3
as well as Week 1 and 2 for bilastine than for placebo. Fexofenadine
also exhibited signiﬁcant improvement in eye itching at all the
examination periods compared to placebo. There were statistically
signiﬁcant differences in eye itching between bilastine and fex-
ofenadine by Week 1. The improvement in lacrimation following
bilastine treatment was weaker than that of the eye itching. On the
other hand, fexofenadine showed a signiﬁcant improvement in
lacrimation at all the examination periods compared to placebo
(data not shown).
Both bilastine and fexofenadine showed signiﬁcantly greater
improvements than placebo in the mean change from baseline in
the TSS by Day 1e3 as well asWeek 1 and 2 (bilastine:0.80 [1.16
to 0.44], P < 0.001 by Day 1e3; 0.51 [0.89 to 0.13], P ¼ 0.009
by Week 1; and 0.47 [0.87 to 0.07], P ¼ 0.021 by Week 2;
fexofenadine: 0.65 [1.01 to 0.29], P < 0.001 by Day 1e3, 0.76
[1.15 to 0.38], P < 0.001 by Week 1; and 0.64 [1.04 to 0.24],
P ¼ 0.002 by Week 2). There were no statistically signiﬁcant dif-
ferences in the TSS between bilastine and fexofenadine.
The exploratory evaluation of the onset of actionwas performed
under natural environmental conditions by assessing the instan-
taneous TNSS on Day 1 (ﬁrst drug administration day). Signiﬁcanteriod in full analysis set (FAS). *P < 0.05, **P < 0.01, and ***P < 0.001 for bilastine or
's t-test).
Table 2
Mean change from baseline in total nasal symptom score (TNSS) by treatment period in full analysis set (FAS).
Placebo (n ¼ 251) Bilastine (n ¼ 249) Fexofenadine (n ¼ 247)
TNSS Baseline Mean ± SD 7.33 ± 1.49 7.48 ± 1.54 7.38 ± 1.43
Day 1e3 Estimated mean change (95% CI) 0.36 (0.55 to 0.18) 0.94 (1.12 to 0.75)*** 0.74 (0.92 to 0.55)**
Week 1 0.48 (0.68 to 0.28) 0.81 (1.01 to 0.62)* 0.91 (1.11 to 0.72)**
Week 2 0.63 (0.85 to 0.42) 0.98 (1.19 to 0.76)* 0.98 (1.19 to 0.76)*
Rhinorrhea Baseline Mean ± SD 2.19 ± 0.63 2.27 ± 0.62 2.25 ± 0.73
Day 1e3 Estimated mean change (95% CI) 0.10 (0.16 to 0.03) 0.30 (0.37 to 0.23)*** y 0.18 (0.25 to 0.12)
Week 1 0.17 (0.24 to 0.10) 0.27 (0.34 to 0.21)* 0.26 (0.33 to 0.19)
Week 2 0.21 (0.29 to 0.14) 0.30 (0.37 to 0.22) 0.31 (0.39 to 0.24)
Sneezing Baseline Mean ± SD 1.55 ± 0.68 1.55 ± 0.66 1.50 ± 0.60
Day 1e3 Estimated mean change (95% CI) 0.10 (0.15 to 0.04) 0.24 (0.30 to 0.18)** 0.23 (0.29 to 0.17)**
Week 1 0.10 (0.16 to 0.04) 0.20 (0.26 to 0.14)* 0.24 (0.30 to 0.17)**
Week 2 0.11 (0.17 to 0.04) 0.23 (0.29 to 0.16)* 0.22 (0.29 to 0.16)*
Nasal congestion Baseline Mean ± SD 1.82 ± 0.57 1.82 ± 0.61 1.82 ± 0.56
Day 13 Estimated mean change (95% CI) 0.08 (0.14 to 0.02) 0.12 (0.18 to 0.06) 0.11 (0.17 to 0.05)
Week 1 0.07 (0.14 to 0.01) 0.11 (0.17 to 0.05) 0.14 (0.20 to 0.07)
Week 2 0.11 (0.18 to 0.04) 0.18 (0.24 to 0.11) 0.17 (0.24 to 0.10)
Nasal itching Baseline Mean ± SD 1.77 ± 0.54 1.84 ± 0.57 1.81 ± 0.55
Day 13 Estimated mean change (95% CI) 0.09 (0.15 to 0.02) 0.28 (0.35 to 0.22)*** 0.21 (0.28 to 0.15)**
Week 1 0.13 (0.20 to 0.07) 0.23 (0.29 to 0.17)* 0.28 (0.34 to 0.22)**
Week 2 0.20 (0.27 to 0.14) 0.27 (0.34 to 0.21) 0.27 (0.34 to 0.21)
Analysis of covariance (ANCOVA) model including treatment as factor with baseline and institution as covariates. CI, conﬁdence interval, SD, standard deviation; *P < 0.05,
**P < 0.01, and ***P < 0.001 for bilastine/fexofenadine vs. placebo. yP < 0.05 for bilastine vs. fexofenadine. Day 13, change in mean score for the treatment period Day 13 (3
days) compared with baseline (for total 4 days: Days 3 to 0). Week 1, change in mean score for treatment period Day 47 (4 days) compared with baseline (for total 4 days:
Day 3 to 0). Week 2, change in mean score for treatment period Day 1013 (4 days) compared with baseline (for total 4 days: Days 3 to 0).
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the instantaneous TNSS 1 h after the ﬁrst drug administration be-
tween the active treatment and placebo, which were maintained
up to the second drug administration on Day 1 (Table 3).
For overall satisfaction with treatment, the percentages of pa-
tients who respondedwith very satisﬁed or satisﬁed during the last
evaluation were 43.8% (109/249), 31.2% (78/250), and 43.7% (108/
247) for bilastine, placebo, and fexofenadine, respectively. Both
bilastine and fexofenadine showed a statistically signiﬁcant differ-
ence in the percentage of patients who responded as very satisﬁed
or satisﬁed compared to placebo (P ¼ 0.004). Moreover, there was
no signiﬁcant difference between bilastine and fexofenadine
(Fig. 4). The rhinoscopic ﬁndings and QOL scores were not signiﬁ-
cantly improved by the active treatments compared with placebo
(data not shown).
Safety
The safety analyses were conducted in the SP, which consisted of
764 patients. The AEs or ADRs reported during the study were mild
or moderate in severity and were similar in type and incidence inTable 3
Mean change from baseline in instantaneous total nasal symptom score (TNSS) 1 hou
administration in full analysis set (FAS).
Baseline n
Mean ± SD
1 hour after ﬁrst study drug administration n
Estimated mean
change (95% CI)
Immediately before second study drug administration n
Estimated mean
change (95% CI)
Analysis of covariance (ANCOVA) model including treatment as factor with baseline and i
**P < 0.01 for bilastine or fexofenadine vs. placebo.the three study groups (AEs: placebo, 4.7%; bilastine, 7.5%; and
fexofenadine, 5.5%; ADRs: placebo, 0.8%; bilastine, 2.0%; and fex-
ofenadine, 2.0%). The proportion of patients who experienced at
least one AE and ADR were similar for all the groups (Table 4,
Fisher's test; AEs: placebo vs bilastine, P ¼ 0.266; placebo vs fex-
ofenadine, P ¼ 0.693; and bilastine vs fexofenadine, P ¼ 0.472;
ADRs: placebo vs bilastine, P ¼ 0.450; placebo vs fexofenadine,
P ¼ 0.285; and bilastine vs fexofenadine, P ¼ 1.000). There was no
AE with a 2% or higher incidence in any of the groups. The AEs were
categorized using the System Organ Class of nervous system dis-
orders, and no patient reported any in placebo while two patients
(0.8%) in bilastine and one (0.4%) in fexofenadine reported som-
nolence. In addition, one patient (0.4%) in bilastine and two (0.8%)
in fexofenadine reported headaches; dizziness postural was re-
ported in one patient (0.4%) in bilastine while one patient (0.4%) in
fexofenadine reported dizziness. There were no serious AEs or
deaths, and no patients withdrew from the study because of AEs.
ADRs were reported by ﬁve patients (2.0%) each in bilastine and
fexofenadine and two (0.8%) in placebo. There were no clinically
signiﬁcant changes in any laboratory test, ECGs, and vital signs from
baseline values in any of the treatment groups.r after ﬁrst study drug administration and immediately before second study drug
Placebo Bilastine Fexofenadine
250 249 246
6.0 ± 2.4 6.1 ± 2.3 6.4 ± 2.6
250 248 246
1.2 1.5 1.6
(1.4 to 1.0) (1.7 to 1.3)* (1.8 to 1.4)**
245 249 245
0.9 1.4 1.5
(1.2 to 0.7) (1.6 to 1.1)** (1.8 to 1.3)**
nstitution as covariates. CI, conﬁdence interval, SD, standard deviation; *P < 0.05 and
Fig. 4. Degree of satisfaction with treatment in full analysis set (FAS). **P < 0.01; Percentage of patients who were satisﬁed or very satisﬁed was compared between placebo and
bilastine or fexofenadine (Fisher's exact test).
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This pivotal phase-III study was the ﬁrst to evaluate the efﬁcacy
and safety of bilastine in Japanese patients with PAR. The results of
the primary endpoint analysis revealed that bilastine signiﬁcantly
improved the TNSS by Week 2 compared with placebo, suggesting
that the efﬁcacy of bilastine 20 mg administered once daily for 2
weeks was veriﬁed to be signiﬁcantly better than placebo.
Following the conﬁrmation of the superiority of bilastine over
placebo, the difference between the efﬁcacy of bilastine and the
reference drug fexofenadine 60 mg twice daily was evaluated using
the primary endpoint. The result showed that fexofenadine
signiﬁcantly decreased the TNSS by Week 2, and there was no
signiﬁcant difference between the active treatments, indicating
that efﬁcacy of bilastine 20mg once daily was comparable to that of
fexofenadine 60 mg twice daily.
While it is important to make informed decisions in clinical
trials based on statistical signiﬁcance, the clinical signiﬁcance or
clinically meaningful differences should also be considered. OneTable 4
Adverse events (AEs) and adverse drug reactions (ADRs) reported over 2-week treatmen
Placebo (n ¼ 255)
n (%) 95%CI (%
Patients reporting 1 AE 12 (4.7) 2.5e8.1
Incidence of AEy
2% in any treatment group 0 e
Withdrawals due to AEs 0 e
Serious AEs 0 e
Nervous system disordersyy 0 (0.0) 0.0e1.4
Dizzinessy 0 (0.0) 0.0e1.4
Dizziness posturaly 0 (0.0) 0.0e1.4
Headachesy 0 (0.0) 0.0e1.4
Somnolencey 0 (0.0) 0.0e1.4
Patients reporting 1 ADR 2 (0.8) 0.1e2.8
Gastrointestinal disordersyy 1 (0.4) 0.0e2.2
Investigationsyy 1 (0.4) 0.0e2.2
Nervous system disordersyy 0 (0.0) 0.0e1.4
Dizzinessy 0 (0.0) 0.0e1.4
Headachesy 0 (0.0) 0.0e1.4
Somnolencey 0 (0.0) 0.0e1.4
Respiratory, thoracic and mediastinal disordersyy 0 (0.0) 0.0e1.4
Skin and subcutaneous tissue disordersyy 0 (0.0) 0.0e1.4
CI, conﬁdence interval; yMedDRA (ver. 17.1) Preferred Term; yyMedDRA (ver. 17.1) Systeobjective approach to determining the clinical signiﬁcance involves
applying the concept of a minimal clinically important difference
(MCID), which is deﬁned as the smallest change in a given outcome
that is meaningful to a patient.19 Higaki et al.20 ﬁrst reported that
calculating the MCIDs for symptoms and QOL scores in Japanese
cedar/cypress pollinosis using the anchor-based approach. How-
ever, to the best of our knowledge, an MCID for PAR has not been
previously determined in Japan. We considered the clinical mean-
ingfulness for the estimated mean difference from placebo at0.35
(95% CI, 0.65 to 0.05) in the bilastine treatment by comparing
with the previous results of intranasal corticosteroid in Japanese
patients with PAR. Okubo et al.21 reported that ﬂuticasone furoate
nasal spray (FFNS) once daily in a dose of 110 mg signiﬁcantly
decreased in change of TNSS from baseline, compared with placebo
(the adjusted mean difference from placebo: 1.119 [95% CI, 1.85
to 0.39]). Since the rating nasal symptoms score was different
among studies (5-point vs. 4-point scale), % reduction of the
adjusted mean difference from placebo at 2 weeks treatment
period in each drug against the adjustedmean change in TNSS fromt period in safety population (SP).
Bilastine (n ¼ 255) Fexofenadine (n ¼ 254)
) n (%) 95%CI (%) n (%) 95% CI (%)
19 (7.5) 4.511.4 14 (5.5) 3.0e9.1
0 e 0 e
0 e 0 e
0 e 0 e
4 (1.6) 0.4e4.0 4 (1.6) 0.4e4.0
0 (0.0) 0.0e1.4 1 (0.4) 0.0e2.2
1 (0.4) 0.0e2.2 0 (0.0) 0.0e1.4
1 (0.4) 0.0e2.2 2 (0.8) 0.0e2.8
2 (0.8) 0.1e2.8 1 (0.4) 0.0e2.2
5 (2.0) 0.6e4.5 5 (2.0) 0.6e4.5
1 (0.4) 0.0e2.2 1 (0.4) 0.0e2.2
0 (0.0) 0.0e1.4 1 (0.4) 0.0e2.2
2 (0.8) 0.1e2.8 3 (1.2) 0.2e3.4
0 (0.0) 0.0e1.4 1 (0.4) 0.0e2.2
0 (0.4) 0.0e1.4 1 (0.4) 0.0e2.2
2 (0.8) 0.1e2.8 1 (0.4) 0.0e2.2
1 (0.4) 0.0e2.2 0 (0.0) 0.0e1.4
1 (0.4) 0.0e2.2 0 (0.0) 0.0e1.4
m Organ Class.
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was calculated. As the results, the % reduction of the adjusted mean
difference from placebo was 56% (95%CI, 8e103%) for bilastine
20 mg, 65% (95%CI, 23e108%) for FFNS, respectively. It has been
generally known that the efﬁcacy of intranasal corticosteroids is
stronger than that of H1-antihistamines,22 therefore, it could be
considered that there were clinically meaningful differences in the
change in TNSS from baseline at Week 2 for both bilastine and
fexofenadine compared to placebo in the present study.
The mean changes in the daily TNSS from baseline for the active
treatments were almost signiﬁcantly different from placebo during
the treatment period. The mean changes in the daily TNSS showed
a largely similar trend from Day 3e13 for the active treatments,
however, the change in TNSS of bilastine was signiﬁcantly greater
than that of fexofenadine was on Day 1. On the other hand, there
was no signiﬁcant difference between bilastine and fexofenadine in
the instantaneous TNSS on Day 1. The daily TNSS reﬂectively
assessed the four nasal symptoms, which were rated daily by the
patients using a 0e4 (3, nasal itching) grading scales. The grading of
sneezing, rhinorrhea, and nasal congestion and itching were eval-
uated based on the frequency of sneezing (number/day), the fre-
quency of nasal blowing (number/day), duration of mouth-
breathing, and duration of nose itching, respectively. The instan-
taneous TNSS were assessed by the patients using the same nasal
symptoms rated on a 0e4 (absentevery severe) grading scale at
predeﬁned times after dosing (1 and approximately 12 h in the
present study). The assessment of the reﬂective and instantaneous
symptoms scoring is recommended by regulatory authorities. The
reﬂective symptom scores assess the overall degree of effectiveness
over a prespeciﬁed time interval, whereas the instantaneous scores
assess the effectiveness at the end-of-dosing interval.23 The
assessment of the instantaneous symptom scores is usually used to
evaluate the efﬁcacy of study drugs in environmental exposure
chamber studies in Japan.24,25 Therefore, there were no critical is-
sues regarding the method used for rating the symptoms scores, as
well as for the evaluation performed based on symptom severity
and timing under natural environmental conditions. Moreover, this
study was a double-blind, placebo-controlled study. Based on these
observations, it might be concluded that the instantaneous TNSS
could be appropriate for evaluating the onset of action under nat-
ural environmental conditions, despite the fact that the ﬁrst clinical
study was performed without validation. The difference between
the daily and instantaneous TNSS values on Day 1 between the
active treatment groups could not be clearly determined based on
the existing factors. However, it might have been caused by dif-
ferences in the grading scales used for both the daily and instan-
taneous TNSS evaluations. Nevertheless, the active treatments
signiﬁcantly improved both the daily and instantaneous TNSS on
Day 1 compared with those of placebo. Furthermore, considering
the rapid onset of action (1 h after dosing), both bilastine 20 mg
once daily and fexofenadine 60 mg twice-daily maintained their
efﬁcacy over the course of one day under natural environmental
conditions in Japanese patients with PAR.
As shown in the daily TNSS results, the mean change in TNSS
and individual nasal symptom score (except nasal congestion) from
baseline at Day 1e3 as well as Week 1 and 2 was almost signiﬁ-
cantly improved following bilastine treatment compared with
placebo. This result suggests that the efﬁcacy of bilastine for the
treatment of nasal symptoms except for congestionwasmaintained
during the treatment period. Similar results were obtained for
fexofenadine, although improvement in the rhinorrhea was not
observed. Therefore, the difference in effects of bilastine and fex-
ofenadine on rhinorrhea might be related to the signiﬁcant differ-
ence observed in their mean change in daily TNSS from baseline on
Day 1, despite the lack of difference in their onset of action.However, we couldn't clearly explain to why change in TNSS of
bilastine was signiﬁcantly greater than that of fexofenadine on Day
1, further experiments will be necessary to clarify it from the
pharmacologic point of view.
The mean change from baseline in TOSS on Day 1e3 andWeek 1
was signiﬁcantly greater for bilastine than it was for placebo;
however, there were statistically signiﬁcant differences in TOSS
between bilastine and fexofenadine by Week 1 and 2. Bilastine
signiﬁcantly improved eye itching but not lacrimation compared to
placebo. On the other hand, fexofenadine signiﬁcantly improved
both eye itching and lacrimation during the treatment period. The
efﬁcacy of bilastine 20 mg once daily in the treatment of ocular
symptoms including lacrimation (tearing in this report) in SAR has
been demonstrated in three overseas clinical studies.26 However,
the efﬁcacy of bilastine on lacrimation symptoms was weaker than
that of fexofenadine in this present study. Further studies would be
needed to conﬁrm the efﬁcacy of bilastine on ocular symptoms for
Japanese patients with AR including SAR.
Both bilastine and fexofenadine showed signiﬁcantly greater
improvements in the TSS on Day 1e3, as well as Week 1 and 2 than
placebo did. Moreover, they showed a statistically signiﬁcant dif-
ference in the percentage of patients that responded very satisﬁed
or satisﬁed compared with placebo. There was no signiﬁcant dif-
ference in the TSS and overall satisfaction with treatment between
the active treatments. Furthermore, the rhinoscopic ﬁndings and
QOL scores were not signiﬁcantly improved by the active treat-
ments compared with placebo.
Although glucocorticoid nasal spray was reported to improve
the rhinoscopic ﬁnding in a randomized, placebo-controlled study
in Japanese adult patients with PAR,21 to the best of our knowledge,
the efﬁcacy of oral H1-antihistamines has not been fully elucidated.
We could not provide a precise explanation for the inability of both
active treatments to improve the rhinoscopic ﬁndings and QOL
scores. However, both bilastine and fexofenadine have lower anti-
inﬂammatory activity than glucocorticoid nasal spray does, which
might be needed for long-term treatment periods of up to 2 weeks.
Regarding safety, there was no difference in the incidence of AEs
or ADRs between bilastine, placebo, and fexofenadine. The inci-
dence of nervous system disorders, which are a classical side effect
of antihistamines, was 0%, 1.6%, and 1.6% for placebo, bilastine, and
fexofenadine, respectively. Therewas no difference in the incidence
of nervous system disorders between bilastine and fexofenadine.
Furthermore, no patients withdrew from this study because of AEs,
and no noteworthy events were observed compared with the ADRs
reported in an overseas study.7
The limitations of this study include the 2-week treatment
period, which may have been too short to simulate actual clinical
setting conditions. There were no concerns in the safety evaluation
in a 1-year administration study conducted overseas.18 However, a
long-term administration study would be required to evaluate the
safety and efﬁcacy of bilastine in Japanese patients with AR.
In conclusion, the results of the present study suggest that
bilastine 20mgadministeredonce daily for 2weekswas an effective
and tolerable for Japanese patients with PAR. Furthermore, bilastine
showed a rapid onset of action (1 h) and the associated change in
TNSS was signiﬁcantly greater than that of fexofenadine on Day 1.
The pharmacotherapeutic characteristics of bilastine 20 mg once
daily for the symptomatic treatment of PAR were similar to those of
fexofenadine 60 mg administered twice daily in the present study.
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